Trial Profile
A Dose Blocked-Randomized, Single-Blind, Placebo-Controlled and Dose-Escalation Phase I Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011 After Intramuscular Administration in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs Toll like receptor 5 agonist - Connext (Primary)
- Indications Acute radiation syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors iNtRON Biotechnology
- 27 Jan 2021 Status changed from recruiting to completed.
- 20 Jul 2018 New trial record